Nobody is trying to be funny here....

Only hunnnned I see is 100% success rate! Guaranteed old sport!

@)-;-Expert resource - GUARANTEES to pass final Audit-;-(@

"ER's approach to Management Systems consulting is very comprehensive, flexible, and affordable. Our consultants maintain a 100% success rate of attaining registration upon first attempt. ER also offers a compliance guarantee! Expert Resource guarantees that your documentation prepared by ER will pass the final audit, regardless of which registrar you choose to audit your management system. Beware of consultants who only guarantee based on the registrar they choose for you."

http://www.expertresource.net/ISO_Systems_index.html

After looking at the chart, it has "breakout" written all over it. IMO of course. I'm not telling anybody to buy or sell, but as for me nothing will change what I believe to be the outcome.

SNDY

@)-;-Expert resource - GUARANTEES to pass final Audit-;-(@

"ER's approach to Management Systems consulting is very comprehensive, flexible, and affordable. Our consultants maintain a 100% success rate of attaining registration upon first attempt. ER also offers a compliance guarantee! Expert Resource guarantees that your documentation prepared by ER will pass the final audit, regardless of which registrar you choose to audit your management system. Beware of consultants who only guarantee based on the registrar they choose for you."

http://www.expertresource.net/ISO_Systems_index.html

SNDY has state-of-the-art devices and will be primed for exit. Investors seemed to be more concerned with pre milestone activity and timetables without understanding future potential impact they provide. We are headed toward a inflection point where much higher values could be generated.




POSTS THAT DESERVE ANOTHER LOOK
(I know I missed a bunch but this is what I could do in the time I had!)


ICHASE01
Wednesday, August 14, 2013 11:09:33 AM
Summary of President's Letter:
1. Stage 1 Audit with TUV SUD America was completed on 2/26/13.
2. Stage 2 Audit for ISO 13485 is scheduled 8/16/13; once completed and CE certification obtained, MammoView devices will be able to be sold in Canada and EU.
3. Solos Endoscopy has retained Emergo Group as authorized representative in Europe.
4. Core business is development and marketing of medical technology, applications, medical devices and procedural techniques.
5. Assets decreased, but so did liabilities.
6. Positive Net Book Value.
7. Increase of sales from same period last year.
8. Increase in revenues.
9. Expenses decreased as did Net Loss.
10. Stock was issued to CEO, not cash, for salary.



MGREGO
Thursday, August 08, 2013 5:34:23 PM

It is pretty much a given that SNDY common shares or Preferred shares would be part of any path to obtaining distribution channels. The shear size of the increase does immediately give the company enormous flexibility to secure a wide variety of deals.

Any M&A (whether Solos is on either end of the equation) or JV would be contingent/necessary on the company increasing its authorized capital (A/S).

An A/S increase is a necessary part of the equation. The condition is often referred to as an amendment to the Articles of Incorporation.




HIGHFLIER
Dilution is paying for the salaries of the folks at SNDY. We have heard a few hundred times how they are screwing us by living it up on our hard earned money. Well that is simply not the case. You need facts, here it is.

The Company decreased its Net Loss for period ended June 30, 2013 by $471,290. The significant financial improvement from the same period in 2012 is due to the fact that the Company will not be charged again
for the issuance of stock to its CEO to guarantee his contract. This improvement of $450,000, combined with an increase in sales of $26,203, resulted in a significant turnaround for the Company. According to Management, total salaries are only $45,404 or approximately 40% of sales. The Company has spent additional monies on professional fees to complete the TUV Audit which is scheduled to take place on August 16, 2013. Therefore, Operating Expenses going forward should remain constant. The reduction of these onetime expenses, coupled with an expected increase in sales the 3rd and 4th quarters in 2013, should result in a very positive end of the year for Solos Endoscopy.

1. According to this their TOTAL SALARIES(plural)is $45,404.
2. The Company has spent additional monies on professional fees to the past several months that all this dilution by the company was to complete the TUV Audit which is scheduled to take place on August 16, 2013. Well according to this additional money has been spent to pay for obtaining the CE mark. Now recently they have hired Emergo Group. Most likely those 100,000,000 million shares was to pay for their services.

Being told they sold millions of shares for the lavish salaries of the folks at SNDY is simply not true.



HIGHFLIER
THE REAL REASON PAST R/S HAPPENED...

I just want everyone to look at the real reasons that are factual as to why SNDY did 4 past R/S. That is what one has to look at and then see if this is the same company now as it was back during the time. Let's consider what was going on during that time.
Solos Endoscopy made a bad business decision when they bought medical devices from Lifeline Bitechnologies for $4 million dollars during tough economic times.

August 2, 2006
Solos Endoscopy Completes Acquisition of Early Cancer Detection Products From Lifeline Biotechnologies for $4 Million
By: Solos Endoscopy, Inc. via Marketwire News Releases

Solos Endoscopy, Inc. (PINKSHEETS: SLSE) today announced the Company has acquired the Lifeline Biotechnologies' early cancer detection product line for $4 Million in restricted shares of Solos Endoscopy. Solos Endoscopy has obtained medical assets from Lifeline Biotechnologies, which included the MastaScope(TM), First Warning System(TM), OvaScope(TM), and the intellectual properties relative, to those products.

Lifeline Biotechnologies will also receive compensation, in the form of a royalty, once sales of the MastaScope(TM), First Warning System(TM), and OvaScope(TM) exceed $4 Million. Lifeline Biotechnologies, Inc. has announced existing shareholders will receive a dividend in Solos Endoscopy for their support of Lifeline Biotechnologies in the development of these products.

Now that these new technologies have been acquired, Solos Endoscopy plans to continue the testing and development of these products in an effort to add them to the current line of women's health care products currently in development at Solos Endoscopy.

"We are happy that we have completed this transaction successfully," stated Jim Holmes, President of Lifeline Biotechnologies.

"We look forward to adding these products to our growing line of endoscopic devices and feel that they will help enhance our position within the women's endoscopic healthcare market," stated Robert Segersten, President of Solos Endoscopy, Inc.

business.highbeam.com/436102/article-1G1-148999918/solos-endoscopy-completes-acquisition-early-cancer


Here we can all see this was toxic for SNDY when they purchased these products for $4 million dollars when the economy was not doing well. They needed to say focused on what they do best and that is make their own medical devices. It was during this time from Aug. 2006 thur Aug. 2010 that the R/S happened. They did need to do R/S to keep the company going. They made a bad mistake in extending themselves in spending $4 million dollars plus royalities during this time.

They were at least smart enough to realize it was time to do something to correct their mistake in buying this from Lifeline. So they sold the devices back to Lifeline Biotechnologies.

Newsline:
Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
March 20, 2009

BOSTON, /-- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has signed an agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) to sell the Ovascope and Mastascope product line to Lifeline Biotechnologies for a combination of stock, assumption of debt and other consideration. Solos Endoscopy originally purchased the products from Lifeline Biotechnologies in 2007.

Lifeline Biotechnologies has agreed to assume a convertible debt from Solos, which will result in less dilution for its shareholders. In addition, the sale of the Ovascope and Mastascope will allow Solos to use its resources to support its expanding core business. Solos is currently in negotiations with Lifeline regarding distribution rights to these products once they are finally ready for the market. Solos will continue to focus its efforts in the area of women's healthcare by concentrating on its Mammoview product line, which is currently sold to hospitals nationwide.

"Although we feel that there is great potential in the Mastascope and Ovascope technology, due to the current state of the economy, our resources will be better utilized in strengthening our current product lines to an expanding customer base," stated Bob Segersten, President of Solos Endoscopy, Inc.

http://boston.citybizlist.com/article/solos-endoscopy-inc-sells-ovascope-and-mastascope-product-line-lifeline-biotechnologies-in-0

Ok now we have some pretty factual reasons SNDY had to do the prior 4 R/S. And to me it would make perfect sense why SNDY had to do those past R/S. It was because they were in major debt because they made a bad choice in an investment decision to buy these medical devices. It happens to companies all the time, not just Solos Endoscopy. As business owners we want to do things to grow our business and we step out and do things that may not of been so great of an idea. But you have to be smart enough and realize when a mistake has been made and correct it. That is what SNDY did.

Did it hurt those investors back then? Absolutely! But it was their choice to be invested in a company that had MAJOR DEBT. I would of NEVER CHOOSEN TO INVEST in a company with that much debt. It was a BAD decision for ANY INVESTOR AT THAT TIME TO have done that. AND SNDY DID NOT make ANYONE invest in their stock. IT WAS A CHOICE, A VERY BAD CHOICE FOR ANYONE TO INVEST IN A COMPANY WITH THAT MUCH DEBT IN A HORRIBLE ECONOMY!!!!

THAT is the real reason why they had to do those past R/S. Bad debt, plain and simple. You never quite tell the real reason why those past R/S happened. But they have turned the corner and the president has said since last year we would see this thru to get the CE mark and then have global distribution of their products bringing value to the share holder. That is about to happen. The future growth of SNDY is about to happen.



HIGHFLIER
both know it was not cheap to hire these companies to get the job done for Solos. It cost money, a lot of money. When I look at these 3 companies, especially Emergo, I think you said it best, PRICELESS. Solos has positioned themselves with some very good companies that can take them to the next level. I just believe the possibilites are endless where this could go, examples: merger/acq./buyout/increase revenue.
People keep thinking only the Mammoview. But I keep looking also at the SteriTap and this article on how huge this market is and the major companies little old Solos is mentioned with:

SOLOS ENDOSCOPY MENTIONED IN $3.6 MILLION LAPAROSCOPIC ARTICLE...

US Laparoscopic Device Market to Grow Moderately to Nearly $3.6 Billion by 2017 Growth Driven by Increasing Demand for Minimally Invasive Procedures, According to Millennium Research Group

January 14, 2013—Toronto—According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for laparoscopic devices will grow moderately, reaching a value of $3.59 billion by 2017. Growth will come largely from expanding procedure volumes, as the demand for minimally invasive techniques continues to grow. Direct energy, hand assist and single-port devices will grow most quickly.

Laparoscopic procedures will grow significantly faster than open surgeries through 2017 as surgeons continue to take advantage of the patient benefits of laparoscopic techniques, such as faster recovery, less post-operative pain, and better cosmetic results. Bowel resections will be the fastest growing laparoscopic procedure, followed by sleeve gastrectomies and hernia repairs. Sleeve gastrectomies will grow at the expense of gastric banding, which has suffered from safety and efficacy concerns.

Single-port procedures will grow strongly, driven by uptake in high-volume procedures such as cholecystectomies and appendectomies. These are procedures where surgeons are either extremely experienced with laparoscopic techniques, or where the anatomy lends itself to straightforward access from the umbilicus.

Robotic techniques will also show strong adoption in urological and gynecological procedures, particularly in prostatectomies, partial nephrectomies and hysterectomies.

“Outside of these growth segments, there is a strong emphasis on cost cutting,” said MRG Analyst Chantal Dougan. “Reusable and reposable products have taken ground from disposable products, particularly in the access device and hand instrument segments. While disposable products generate higher per-procedure revenues, over the next few years the conversion to reusable devices will aid revenues, as facilities invest in entire sets of reusables.”

CareFusion, Solos Endoscopy and Integra LifeSciences all launched modular reusable hand instruments in 2012 to combine convenience with cost-savings.

Here we see Solos is getting mentioned with some big name companies. These people writing these article know the products SNDY has. And out of all the companies they could of mentioned they DID MENTION SNDY!! SNDY spending the money last year to bring out new products is going to pay off big time. They know their market and are taking every step to position themselves to be a player in this market. And a company like Emergo Group can get this type of product into a Global market quickly.



HIGHFLIER
I SURE HOPE EMERGO GROUP IS OUR PARTNER....

Emergo Group consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution. Who will help us in distrubution? A group of their consultants.

So here is one of their distribution consultants

David Christie, BSc, MBA
Distribution Consultant
David Christie is a highly accomplished President and Chief Executive Officer with a proven ability for commercializing technology, facilitating change and increasing shareholder value by delivering compelling financial results. Unique combination of experiences in early stage start-ups, turnarounds, revenue and profit acceleration, mergers and acquisitions across various industries, including environmental, information/communication technologies and medical devices. Mr. Christie’s strengths include implementing strategic change – quickly analyzes the current situation, creates a compelling vision for the future, documents the action plan to move from here to there and executes on the plan with tenacity and precision; delivering financial results – very adept at improving revenue and profit performance through sustainable growth and with appropriate financing; effectively commercializing technology – understands the challenges of turning brilliant concepts in to inventions, creating an effective intellectual property portfolio, overcoming regulatory, reimbursement, quality, manufacturing and logistic challenges, to deliver products to market and realize double-digit returns on investment, especially with innovative new technologies.
EXPERIENCE:
Christie Consulting Services – 2009 to present
Christie Consulting is a sole proprietorship dedicated to helping early-stage and emerging technology companies expand their business. By working with the client’s senior executives in a collegial, advisory and consultative capacity, Christie adds real value by objectively analyzing their business problems, identifying opportunities to accelerate growth and rolling up his sleeves to make results happen. Leveraging his broad and deep experience, he is able to contribute quickly and effectively. Clients include:
• Romich Medical – very early stage, exploring new gynecological applications for existing medical devices
• ARC Pharmaceuticals – early pre-clinical commercial stage, assessing clinical markets here and abroad
• Emergo Group – international regulatory and distribution firm, providing Canadian market assessments
• Hemosonics – start-up stage, advisor to the CEO on all aspects of technology commercialization


So what about the president of Emergo Group:

René van de Zande
President & CEO
René is responsible for all operations of the Emergo Group of companies worldwide. René founded Emergo Group in 1997 and as its President & CEO, he has a consistent record of delivering results in growth, revenue, operational performance, and profitability. Today, he spearheads the international expansion of Emergo Group's operations and service offerings, and provides guidance and support to Emergo Group teams on five continents.


www.massdevice.com/emergo-group-doubles-office-space-accommodate-growth
Emergo Group doubles office space to accommodate growth
Emergo Group, an international regulatory consulting firm, has completed a move into its new headquarters in downtown Austin, leasing more than 13,000 square feet at 816 Congress Avenue.The expansion comes in response to strong demand for the company’s services from medical device manufacturers in the US, Canada and Europe. Emergo Group specializes in assisting medical device companies with US and international regulatory compliance. The company currently employs 55 people at its headquarters in Austin, with plans to continue hiring throughout 2013.

Asked about the driving factors for growth at the company, Emergo Group President and CEO Rene van de Zande notes: “We’re seeing strong demand from companies that want to expand overseas, but might have been intimidated by the regulatory process. That’s especially true in challenging markets such as China, Brazil, Japan, Mexico and Russia, where having local expertise is key. We now have offices in 23 countries, which allows us to help our 2,500 clients grow by accessing markets they might not otherwise have considered.”

Emergo Group plans to expand throughout 2013, with new offices planned for the Middle East, South America and Southeast Asia.

“We don’t see things slowing down. Healthcare spending continues to rise, especially in fast growing markets like Brazil and China. Medical device companies in the US and Europe are looking for ways to boost the top line and the rate of growth in those countries far exceeds what they can expect in their home markets,” notes van de Zande.

About Emergo Group

Emergo Group is an international medical device consultancy serving medical device companies in 55 countries worldwide. The firm assists manufacturers with medical device registration, quality system compliance, clinical trials, in-country representation, reimbursement and distributor search consulting. The company was founded in 1997 and can be found online at www.emergogroup.com

Emergo Gruop knows people on top of people. They are beyond connected across the world. If they have a product then it will have the attention of the companies they distribute to. The possibilities are endless with how all this will unfold with SNDY over the next 2-4 months.


HIGHFLIER
LOOKS LIKE SNDY JUST STEPPED UP THEIR GAME...

in the hiring of Emergo Group. SNDY is taking this final audit as serious as they can. Not only do they have Expert Resources to over see this audit but have now brought in Emergo.
What is Emergo role? Here we go:

ISO 13485 Audits for Medical Device Companies.

Medical device manufacturers are required to regularly conduct an audit of their ISO 13485 compliant quality management system. Emergo Group conducts these fully independent quality system reviews for companies that are already ISO 13485 certified as well as for firms about to undergo their initial ISO 13485 certification audit by a Notified Body or Registrar.

Not only that but look how well Emergo takes care of their customers once hired:

Emergo Group provides the following ISO 13485 auditor services:
These ISO 13485 audits help determine the actual status of your current quality management system and processes:

•Off-site review of your current QA/RA documentation prior to your on-site ISO 13485 audit by a Notified Body or Registrar
•Systematic and independent process audit to determine conformity or nonconformity of your Quality Management System to ISO 13485:2003 requirements
•Review of your internal documentation to verify that all requirements have been addressed
•Actual verification of ISO 13485 audit requirements through review of objective evidence
•Physical verification of compliance via interviews and fact-based observations to confirm quality system requirements
•Evaluation of current special controls or validated processes; knowledgeable in various processes such as sterilization, clean-rooms, or software systems

Emergo Group also provides on-site ISO 13485 auditor training in order for clients to effectively audit their own quality systems. Our training is classroom-based and teaches your employees how to become ISO 13485 internal auditors to ensure proper functioning of your QMS. Key topics of the training include why ISO audits are required, planning an internal audit, as well as conduct and performance issues related to ISO 13485 internal audits.

CE Certification – CE Mark Certification for Medical DevicesSee all regulatory consulting services and medical device registration services.

In order to commercialize medical and in vitro diagnostic devices in the European Union, manufacturers must obtain CE Marking certification and affix the CE marking as part of their device registration efforts.

CE Marking certification verifies to EU regulators that your device meets all requirements of the Medical Devices Directive (MDD), In Vitro Diagnostic Device Directive (IVDD) or Active Implantable Medical Device Directive (AIMD) as they apply to your product. You must obtain CE Marking certification prior to marketing, distribution and sale of your product in any EU member state.

You are solely responsible as the medical device manufacturer for maintaining compliance with EU directives and securing CE Marking certification for your product, regardless of whether you outsource any or all components of your manufacturing operation.

Qualifying for CE certification and marketing your medical device in the EU requires the following steps:

1.Prepare a CE Marking Technical File or a Design Dossier for a Class III device that includes data proving compliance with the MDD, IVDD or AIMD.
2.Obtain your CE Marking certificate from a Notified Body.
3.Select and appoint a European Authorized Representative to act on your behalf within the EU.
4.Register your medical device with the appropriate Competent Authority, if necessary.
Completion of these requirements allows you to claim CE Marking certification for your device.

Looks like to me SNDY just took care of #3 with todays news.
Emergo Group has a well-established presence in the EU, with offices in the UK, Germany, France and the Netherlands. We have assisted hundreds of medical device manufactures with their CE Marking certification efforts. Services we provide to help you obtain CE certification include product classification; technical file and design dossier preparation; ISO 13485 quality system implementation and auditing; and ISO 14971 risk assessment and management.

Why choose Emergo Group as your ISO 13485 consultant?

With over 20 local offices worldwide, Emergo Group has helped hundreds of medical device and IVD manufacturers implement quality systems that meet the ISO 13485 standard. Our team of experienced ISO 13485 consultants have implemented numerous quality management systems for companies manufacturing a wide range of medical devices.

Our system has been proven to work efficiently and we have been through the process with many medical device and IVD companies that we guarantee you will pass your first ISO certification audit if you follow our plan.

•We fully customize ISO 13485 quality systems for our clients.
•Our ISO 13485 consulting and project management teams will work closely with you to ensure that your quality system is implemented on time and on budget.
•On-site ISO 13485, CE Marking, and Canadian Medical Devices Regulations training for your key employees is included in the cost of an Emergo Group quality system.
•All of our projects are based on a fixed price.


CE Mark Consultants and CE Marking for Medical Devices

Before you can sell a medical device or IVD within Europe, you must obtain CE Marking certification and place a CE Mark (CE Marking) on your product. The CE Marking for medical devices is not a quality mark nor is it intended for consumers. It is a legally binding statement by the manufacturer that their product has met all of the requirements of the Medical Devices Directive (MDD 93/42/EEC), In Vitro Diagnostic Device Directive (IVDD 98/79/EC) or the Active Implantable Medical Device Directive (AIMDD 90/385/EEC), where applicable. If a Notified Body is required, the Notified Body's four-digit number would appear below the CE Marking symbol.

CE Marking Checklist:
The Medical Devices Directives state that companies must do the following before they can place the CE Marking on a medical device or IVD:

•Compile a medical device CE Marking Technical File (or Design Dossier for Class III) with evidence of compliance to the Medical Devices Directive (or the IVD/AIMD Directives).
•Receive a medical device CE Mark certificate from a Notified Body if Class I with Measuring or Sterile function, Class IIa, IIb, or III, or if Annex II, List A; Annex II, List B, or self-testing IVD.
•Appoint a European Authorized Representative if you have no physical location in Europe.
•Register medical devices with the EU Competent Authorities, where applicable.

Only after these CE Marking requirements are satisfied are you allowed to place the CE Marking on your medical device.

Our CE Marking Services:
Emergo Group has assisted hundreds of companies with medical device CE Marking. Our services include:

•CE Marking Technical File or Design Dossier compilation and review.
•Verification of Essential Requirements.
•Product classification and identification of applicable standards for medical devices.
•Implementation and maintenance of ISO 13485 quality systems.
•Product labeling and packaging review.
•Risk assessment and management (ISO 14971).
•Development of Vigilance and Post Market Surveillance including Vigilance Standard Operating Procedures and Processes.
•Authorized Representative for Europe.
Our quality management systems can meet European CE Marking & other international requirements
Emergo Group can develop a compliant quality management system by applying ISO 13485:2012 to ensure you meet the quality system requirements for Europe. Each system is customized for the manufacturer and can not only ensure compliance to the European Directives for Medical Devices (CE Marking), but also to the Canadian Medical Devices Regulations, United States FDA QSR, Australian TGA requirements, and Japanese Pharmaceutical Affairs Law.

This place is like a Wal-Mart for your one stop shop for all your shopping needs.
Medical Device Logistics ConsultingEmergo Group can assist you with determining the best solutions for shipping your products. When exporting products many medical device companies start by shipping orders direct to distributors or customers. However, as the frequency of orders and order volumes increase it may become lucrative to consolidate orders in bulk shipments or to establish a suitable warehousing arrangement.

Warehousing & Transportation
In situations where companies are shipping direct to multiple distributors or customers, consolidation of these shipments may result in significantly lower shipping costs. And instead of requiring each distributor to keep a minimum inventory level, you as the supplier can decide to keep products warehoused in a centralized location to reduce total inventory levels in the supply chain while maintaining the option to ship next day to the distributors and customers. Results are cost savings in the supply chain, higher service levels to distributors and customers, and increased market share.

When importing products into Europe and warehousing these products in a centralized location, customs duties and value added tax (VAT) apply.

Customs Duties and Value Added Tax (VAT)
Postponement of customs duties can be arranged by warehousing your products in a customs bonded warehouse for an unlimited period of time. During this period no customs duties are due. Customs duties at import need to be paid when the goods are actually imported into the free circulation of the European Union.

Value Added Tax (VAT) is due upon import of products into the European Union and varies per EU country from 15-25%. This is a supply chain tax, and is refundable to businesses, usually by submitting a quarterly VAT return.

Finding and selecting warehousing & transportation partners
When looking for a third party logistics provider for your European warehousing and transportation needs, we can assist you with the following:

Step 1: Determine your medical device logistics needs
Depending on if you are starting up or optimizing your logistics operation(s), your needs can range from a distribution location to warehouse, pick, and ship your products to a full service value-added logistics facility where products can be assembled or customized to the specific needs of your customer base. The choice is yours! It is also possible to select a logistics provider as your fiscal representative.

Step 2: Identify potential EU logistics providers
Through our extensive logistics experience and existing network we are very familiar with the capabilities of logistics service providers specialized in medical devices. Based on your logistics needs we can identify the logistics providers that best fit your needs.

Step 3: Meet with potential logistics partners
Seeing is believing! We can set up on-site meetings for you with logistics providers that fit your needs and if required accompany you on these visits.

Well we don't know what it cost to hire Emergo Group, but I can say this, job well done SNDY for hiring such a great company to take this stock to the next level. If you had to sell some shares to make this happen, you spent our money well. I for one never questioned what was happening behind the doors at SNDY. I guess you can say the quite period is now over. I have said for the past 4 months when they have something of importance to tell us they will. I want to thank all the longs that has believed in SNDY over the past year and contributed to this board. I guess all those people spending 1.6 million dollars in SNDY preferred shares believed in them as well. We all know they was betting on the future of this company as well.


TANGERINE
Thursday, August 15, 2013 12:13:17 AM

My conclusion thus far.

The CE mark is a significant milestone. Those on both sides of the argument seem to clearly believe this. With all of the arguments against SNDY, it is clear all believe this to be a big achievement for the company and a lot of money and dilution has gone into ensuring this would happen. So all sides including the company believe this is a big achievement.

Will this CE mark generate significant revenue? Not by itself but it opens markets. Who will be selling this product and who will be buying these products? Who knows at this point. I haven't seen a real answer but it would be a prerequisite to sell the company or merge.

I also don't see anyone arguing that mammoview does not work. So that would be the biggest and best argument to me but it is pretty obvious to me and from reading some of the technical docs, that it probably does work. How come it hasn't been picked up more my others, journals, every hospital in the free world wanting it? Does make you wonder.

I don't see any real short volume and I am not sure you even could short this stock. The downside and upside and the fees probably make this a poor choice.

Is the argument really about a trading opportunity and entry price? Probably, at least it would seem that way.

Buyout? For the tech maybe but the trading wouldn't indicate it so far from what I can see but maybe with CE mark as some are predicting.

Will I buy some more shares? Probably


AQUA
Thursday, August 15, 2013 1:24:01 AM
To bring this into perspective, Solos management realized a long time ago that their products have not met much success in the US healthcare system in terms of revenues and profitability. Their strategic initiative objective was to open Solos to new markets. But the only barrier to entry into the markets in Europe and Canada was obtaining the expensive CE Mark certification. In the process, Solos had to make sacrifices, which were unfortunately at the expense of shareholders after multiple attempts of dilution to their stock. Keep in mind that management's ambition to pursue the CE Mark is valid given the survival of the company is at stake due to least spectacular product sales. With one day away, we await a defining moment in Solos history and its existence as a global company with the purpose of saving lives. Cheers!


SimmerDownNow
Shh... there's an audit going on.
Go SNDY!


EKIM88


ELCAPPY1
3 Month Daily Chart

200MA Leveling out as Resistance...
50MA Turning up for higher levels of support...

Keep in mind what happens when the 50MA crosses above the 200MA with stellar news to back it... Future short term press releases, ISO 13485 (2+yr process), C.E. Certification (2+yr process), Limited Dilution (ISO & CE paid for), New partnerships, Merger, Acquisitions, Share buyback, Retirement of shares, Dividend...

2 Year Daily Chart
Please take a look @ January 2012. This 1000%+ run to the end of March was caused only by the ANTICIPATION of the Stage 2 Audit August 16th 2013... Please take note to the mid March Golden Cross...

2 Year Weekly Chart

EXTREMELY BULLISH
RSI 49.04
20MA RED
50MA BLUE

Chart breakdown - 8/17/2013

Expert resource - GUARANTEES to pass final Audit

"ER's approach to Management Systems consulting is very comprehensive, flexible, and affordable. Our consultants maintain a 100% success rate of attaining registration upon first attempt. ER also offers a compliance guarantee! Expert Resource guarantees that your documentation prepared by ER will pass the final audit, regardless of which registrar you choose to audit your management system. Beware of consultants who only guarantee based on the registrar they choose for you."

http://www.expertresource.net/ISO_Systems_index.html

Please let's see what deserves credit....


Trips? Nope
RS? Nope
.0016? Nadda
.0009? Zip
Stage 1 audit? No delay and was successful....yup wrong again
Stage 2 audit? No delay..... Not this one

Now lets see what happens next.

A/S was expected. This is common before M/A, so really do you feel as if credit should be due for this?

I know I'm not the only one who saw the 6 market makers trying franticly to keep the price below .0033 the past couple of weeks. Looks to me they want to make it look like a wall, but I don't honestly believe they want to sell many shares. I mean if they did why didn't they just sell at .0031 or .0032? Instead they pile up on .0033?

I'm buying more when I see a PR of successful Audit.

Today is the day for the Audit, nobody is changing their position. Lets see what the results are before anybody starts pointing fingers.

SNDY is holding just fine, we will be hearing from them real soon. ISO 13485 is a game changer. When they pass the audit, to me that's just like slapping the marks right on there products that day.

And when that happens SNDY is a new company, one that can not be compared to itself 3 years ago.

Everybody knows it. Sorry but SNDY is going up.

It will be a great day for shareholders to receive confirmation that Audit 2 was successful. They will receive CE mark soon after.

Has anybody found another pink trading at this level with FDA & CE mark? Still looking.........

Agreed, lots of accumulation at this level by the MM's. Wouldn't be surprised to see 40%+ next week.

I know I'm trading in the pinks, therefore I have to adjust my point of view to reflect it. With SNDY I noticed something different, and unlike any other pink it actually surprised me to see that SNDY was actually using the funds to bring value and growth to the company. Delays are unpredictable, and if the end result is achieved well...its really the only thing that matters to me.

Highflier, according to this diagram from the TÜV website, it showing a time period of 3-8 weeks to be issued certificates. Is that just the ISO 13485 or will that both ISO and CE mark?

Also I have heard of instances where the majority of the paperwork to receive the CE mark is done at the same time as the final audit to speed up the process. Do you think this could be a possibility?

To see the PR about successful Audit 2 will be so satisfying!

ISO 13485 will look good, and CE markings will look even better on all their products.

GLTA SNDY

Well hopefully you will be around when it does...

Tomorrows successful completion of the Stage 2 Audit, including a review of the Auditor’s report and resolution to any corrective actions, Solos will be certified to ISO 13485:2003, the internationally recognized standard for quality systems for medical device manufacturers. Certification to ISO 13485:2003 will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union.

http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=109547

CE marking approval, is but one of many important value inflection points in the entire lifecycle of the company...

Nice post

SNDY CHARTS

Nice Post ELcappy1

3 Month Daily Chart

200MA Leveling out as Resistance...
50MA Turning up for higher levels of support...

Keep in mind what happens when the 50MA crosses above the 200MA with stellar news to back it... Future short term press releases, ISO 13485 (2+yr process), C.E. Certification (2+yr process), Limited Dilution (ISO & CE paid for), New partnerships, Merger, Acquisitions, Share buyback, Retirement of shares, Dividend...



2 Year Daily Chart

Please take a look @ January 2012. This 1000%+ run to the end of March was caused only by the ANTICIPATION of the Stage 2 Audit August 16th 2013... Please take note to the mid March Golden Cross...



2 Year Weekly Chart

EXTREMELY BULLISH
RSI 49.04
20MA RED
50MA BLUE

R&D is what they are really trying to sell, 25 years of it.

This may help understand...

February 13, 2007 -- Solos Endoscopy, Inc. announce that the Company's board of directors has approved a new acquisition and merger strategy.

"Our strategy through mergers and acquisitions is to continue offering top-of-the-line medical products while developing innovative new devices and increasing our presence in the endoscopic market," stated Bob Segersten, President of Solos Endoscopy, Inc.

If unreadable, the heres the link page 80,81,82


http://dspace.mit.edu/handle/1721.1/37978

http://www.solosendoscopy.com/products.html

http://www.solosendoscopy.com/pdf/Sept-27-2012-Solos-Endoscopy-Celebrates-25-Years-of-Quality-Innovative-HealthCare-for-the-Multi-Billion-Dollar-Endoscopic-Market.pdf

When the president of the company mentions the date in a letter to share holders 2 days before the Audit, I'm pretty confident that theres no delay...

as far as the schedule on their website....

Definition....

Schedule (project management):a list of a project's milestones, activities, and deliverables with intended start and finish dates

I agree, SNDY will help in bringing affordable early detection to many which in turn will save lives. Even if they sold one, that one MammoView could help and save numerous lives by detecting breast cancer at its earliest stages.

I believe when a company reaches a milestone such as CE Mark, this changes the company entirely. A new chapter is written from that day forward, IMO and it all starts with a successful Audit. You just wouldn't be able to compare the SNDY R&D startup with the SNDY FDA & CE global distributer.

Glad to have you on the boards, your input is always appreciated!

SNDY is a champ, success on Friday IMO

Looks like SNDY is holding well, when the time comes she will run....

Yeah if that was the case they would sell at a lower PPS...

Nope, I didn't see it.

Emergo group will be a nice fit for SNDY, big sign of growth IMO.

With ISO 13485 completed it will further support the positive direction we are headed.

A rare gem, FDA & CE mark in the pinks. Can't wait!

GLTA !

8/14/13. Dear Solos Endoscopy, Inc. Shareholders,
I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update on our impressive progress for the second quarter; the three month period ended June 30, 2013.
Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 25 years. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.
Solos Endoscopy completed the Stage 1 Audit with TÜV SÜD America on Tuesday, February 26, 2013. Solos Endoscopy's Quality Manual and 28 Quality System Procedures were reviewed by TÜV SÜD for compliance to the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Stage 1 Audit, the Company has been diligently working, with the support of Expert Resources, to continually develop, implement and master the Quality Manual and Quality System procedures.
Solos Endoscopy and TÜV SÜD America has scheduled its Stage 2 ISO 13485 Audit to be completed on August 16, 2013. Upon successful completion of the Stage 2 Audit, including a review of the Auditor’s report and resolution to any corrective actions, Solos will be certified to ISO 13485:2003, the internationally- recognized standard for quality systems for medical device manufacturers. Certification to ISO 13485:2003 will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. According to a 2009 report published by Frost & Sullivan, the European Union represents $94 Billion, or 30%, of the worldwide demand for medical instruments. ISO 13485:2003 certification is also necessary for the company to sell the MammoView® product line in Canada. Recently, as part of the process to obtain the CE Mark, Solos Endoscopy has retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.
The company previously was successful in completing the Food and Drug Administration (FDA) Level II Baseline Inspection in which it received a NAI (No Action Indicated) for the inspection. It is standard for the FDA to perform unannounced inspections periodically for medical device manufacturers, and the successful inspection by the FDA validates the Company's quality system and its strict adherence to that system.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. The Company is currently marketing its next generation breast endoscopy system, the MammoView® system, for early breast cancer detection.
Solos Endoscopy’s core business is the development and marketing of medical technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Solos Endoscopy 2nd Quarter 2013 Analysis
Balance Sheet
Solos Endoscopy’s Total Assets decreased to $2,262,785 for the period ended June 30, 2013 from $2,426,883 for same period in 2012. This represents a decrease of ($164,098), which is mainly attributable to a cash and inventory decrease of more than $167,000 for the period ended June 30, 2013 as compared to the same period in 2012.
Solos Endoscopy reduced its Total Liabilities from $214,827 for the period ended June 30, 2012 to just $148,000 for period ended June 30, 2013. As a result, the Company has a Positive Net Book Value when it posted its financials for the period ended June 30, 2013.
Income Statement
Solos Endoscopy showed an increase in sales from $81,752 for period ended June 30, 2012 to $107,955 for period ended June 30, 2013. This represents an increase in revenues of $26,203. The Company’s Gross Profit increased from $53,214 for period ended June 30, 2012 to $59,520 for the period ended June 30, 2013. The Company’s Cost of Goods increased by more than $18,000 as a result of the Company writing off obsolete inventory in the 2nd Quarter.
Solos Endoscopy’s Total Expenses decreased from $642,963 for period ended June 30, 2012 to $177,978 for period ended June 30, 2013. The significant decrease in Total Expenses is due to the $450,000 expense the Company incurred for stock issued to the CEO in 2012 to guarantee his contract. Otherwise, the Company actually reduced its General and Administrative Expense from $192,963 for period ended June 30, 2012 to just $177,978 for period ended June 30, 2013.
Conclusion
The Company decreased its Net Loss for period ended June 30, 2013 by $471,290. The significant financial improvement from the same period in 2012 is due to the fact that the Company will not be charged again for the issuance of stock to its CEO to guarantee his contract. This improvement of $450,000, combined with an increase in sales of $26,203, resulted in a significant turnaround for the Company. According to Management, total salaries are only $45,404 or approximately 40% of sales. The Company has spent additional monies on professional fees to complete the TUV Audit which is scheduled to take place on August 16, 2013. Therefore, Operating Expenses going forward should remain constant. The reduction of these onetime expenses, coupled with an expected increase in sales the 3rd and 4th quarters in 2013, should result in a very positive end of the year for Solos Endoscopy.
In closing, I want to thank our shareholders for your patience and continued support of Solos Endoscopy. We will continue to keep our shareholders updated through regular posting on www.otcmarkets.com and Company press releases. To learn more information about the Company and its products visit www.solosendoscopy.com.
Regards,
Robert Segersten
President and CEO
Solos Endoscopy, Inc.

Certain statements in this document may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this document, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Okay who bought in 2010 can they post please?

IMO, many are waiting for successful stage 2 results.

They are opinions when you add words like addicted, massive, or devastating.

Thanks for your opinions, but SNDY has again built my confidence as a shareholder. Exciting times for SNDY.

Nice post, seems to me that Emergo Group is just what they need.

Quote:
The net loss cut of 46% will be attractive for any merger/acq/buyout or if they are just plan old gearing up for global distribution of sales. And by SNDY hiring Emergo Group they just added huge leverage in making any of the above happen.

Consider just one of Emergo Groups consultants resume:

David Christie, BSc, MBA
Distribution Consultant
David Christie is a highly accomplished President and Chief Executive Officer with a proven ability for commercializing technology, facilitating change and increasing shareholder value by delivering compelling financial results. Unique combination of experiences in early stage start-ups, turnarounds, revenue and profit acceleration, mergers and acquisitions across various industries, including environmental, information/communication technologies and medical devices. Mr. Christie’s strengths include implementing strategic change – quickly analyzes the current situation, creates a compelling vision for the future, documents the action plan to move from here to there and executes on the plan with tenacity and precision; delivering financial results – very adept at improving revenue and profit performance through sustainable growth and with appropriate financing; effectively commercializing technology – understands the challenges of turning brilliant concepts in to inventions, creating an effective intellectual property portfolio, overcoming regulatory, reimbursement, quality, manufacturing and logistic challenges, to deliver products to market and realize double-digit returns on investment, especially with innovative new technologies.
EXPERIENCE:
Christie Consulting Services – 2009 to present
Christie Consulting is a sole proprietorship dedicated to helping early-stage and emerging technology companies expand their business. By working with the client’s senior executives in a collegial, advisory and consultative capacity, Christie adds real value by objectively analyzing their business problems, identifying opportunities to accelerate growth and rolling up his sleeves to make results happen. Leveraging his broad and deep experience, he is able to contribute quickly and effectively.

Clients include:
• Romich Medical – very early stage, exploring new gynecological applications for existing medical devices
• ARC Pharmaceuticals – early pre-clinical commercial stage, assessing clinical markets here and abroad
• Emergo Group – international regulatory and distribution firm, providing Canadian market assessments
• Hemosonics – start-up stage, advisor to the CEO on all aspects of technology commercialization

Why bring this up. Because in the new release last week about Emergo Group it stated, "Emergo Group consultants will assist Solos with a wide variety of regulatory, quality assurance, and distribution". That is exactly what Mr. Christie does for Emergo Group, a consultant who helps with distribution and merger and acq. You get my point.

The time is coming when news is going to break of a merger/acq/buyout or global distribution of their products. Either way I believe we the share holders win.

Take care my friend,
Mike

so you don't believe a company needs to raise the A/S before a merger/acquisition to protect themselves from a hostile takeover.

interesting.

So your frightened of the thought of delay in achieving CE MARK?

so when will the scary finishing move "The Leg Drop" that will let us know sndy is out for the count? after or before Audit?

Questions....

Thanks for the opinions

Do you know of any pinks who have FDA and after receiving CE mark fall to the trips with a R/S? how about one? Seems to me that a milestone such as CE mark is a game changer, does that make any difference?

What do you think about 95% exit via merger/acquisition when receiving both CE mark and fda approval. Do you think this was imaginary and is not important?

How about the scheduled Audit stage 2... You believe it was imaginary as well?

Will Expert Resources have its first failed audit staining its 100% success rate?

Does Robert Segersten plan on diluting when hes 90 years old?

Does your opinion change if you have a position in sndy?

Do you still think the PPS will go to .0009 this week?month?year?

Should I load up at .0009 but watch out for the R/S at the same time?

Well everyone agrees (Including yourself) a company need to raise the A/S before a merger/acquisition to protect themselves from a hostile takeover.

(@)-;--'-FINAL AUDIT #2 FRIDAY 8/16-'--;-(@)

@)--;--WELCOME TO SOLOS ENDOSCOPY--;-(@

I KNOW MOST ON THIS BOARD WASN'T EXPECTING THIS...

Revenue up 24%, net loss cut by 46%.
Just a start of what should continue to better for this company.

Revenue up 24% from $81,752 up to $107,955
Net loss cut by 46% from $458,665 down to $246,738

Company is moving in the right direction. Better things to come after Aug. 16th audit.

If a company was trying to screw over the share holders, there is no way in hell they would be cutting net loss, especially by 46%!!!!!!! Merger/Acq/Buyout or major distribution channels to sell their product in a global market which we send revenue up in the 100's% range. Take your pick one of them is coming. 95% odds say a merger/acq. Not betting against that!

Take care my friends,
Mike
THIS IS A VERY EXCITING TIME AS SNDY IS EMERGING INTO A NEW LEVEL.
SNDY HAS MADE MANY ADVANCEMENTS IN THE PAST 3 YEARS

A COMPANY THAT FOCUSES ON RESEARCH & DESIGN, ITS PRODUCTS ARE STATE OF THE ART AND HAVE SHOWN TO DETECT BREAST CANCER IN THE EARLY STAGE THAT CAN BE UNDETECTABLE WITH STANDARD MAMOGRAPH CHECKUPS.

SNDY IS SAVING LIVES, AND THAT IS A FACT

THE DEMAND FOR EARLY DETECTION IS INCREASING RAPIDLY

SNDY WILL MEET THAT DEMAND





_____________________________________________________________

SNDY A REAL COMPANY
SNDY IS LIKE NO OTHER PINK (DO THE DD)
SNDY AS A COMPANY IS EMERGING INTO A NEW MARKET
SNDY HAS OVER 200 FDA APPROVED MEDICAL DEVICES
SNDY MANAGEMENT AGREED ON A MERGER/ACQUISITION PLAN IN 2007

*****

SNDY HAS COMPLETED AUDIT STAGE 1 FOR ISO 13485 WITH NO DELAY
SNDY HAS A SCHEDUALED AUDIT WITH TÜV ON 8/16/2013
SNDY WILL HAVE THE GREEN LIGHT TO OBTAIN CE MARK
SNDY HIRED EXPERT RECOURCES TO ENSURE SUCCESFUL COMPLETION
EXPERT RECOURCES HAS A PERFECT RECORD IN PASSING AUDITS.
SNDY HIRED EMERGO GROUP AS THEIR EUROPEAN ATHORIZED REPRESENTIVE




*****

SNDY will be FDA + ISO 13485 + CE Mark approved (VERY RARE IN PINKS)
SNDY WILL OPEN DOORS TO A 90+ BILLION DOLLAR MARKET WITH CE MARK
95% of small company's who have FDA and CE mark exit via merger/acquisition


http://dspace.mit.edu/handle/1721.1/65522


*****

insert-text-here
http://www.zapconnect.com/companies/index.cfm/fuseaction/companies_detail/eregnum/1223105.html#!/exjun_

*****
SDNY WILL RECIEVE AND HAVE THESE MARKS SOON AFTER SUCCSEFUL AUDIT COMPLETION.


THESE BILLION DOLLLAR COMPANYS DEPEND ON THE R&D OF SMALLER COMPANIES TO GROW THEIR CATALOGS AND TO DOMINATE THE MARKET BY BUYING THEIR COMPETITORS

*****

insert-text-here




*************LOCATION & HEADQUARTERS**************


SOME GREAT POSTS ON THE SNDY BOARD

[url]Quote:
--------------------------------------------------------------------------------
LOOKS LIKE SNDY JUST STEPPED UP THEIR GAME...

in the hiring of Emergo Group. SNDY is taking this final audit as serious as they can. Not only do they have Expert Resources to over see this audit but have now brought in Emergo.
What is Emergo role? Here we go:

ISO 13485 Audits for Medical Device Companies.

Medical device manufacturers are required to regularly conduct an audit of their ISO 13485 compliant quality management system. Emergo Group conducts these fully independent quality system reviews for companies that are already ISO 13485 certified as well as for firms about to undergo their initial ISO 13485 certification audit by a Notified Body or Registrar.

Not only that but look how well Emergo takes care of their customers once hired:

Emergo Group provides the following ISO 13485 auditor services:
These ISO 13485 audits help determine the actual status of your current quality management system and processes:

•Off-site review of your current QA/RA documentation prior to your on-site ISO 13485 audit by a Notified Body or Registrar
•Systematic and independent process audit to determine conformity or nonconformity of your Quality Management System to ISO 13485:2003 requirements
•Review of your internal documentation to verify that all requirements have been addressed
•Actual verification of ISO 13485 audit requirements through review of objective evidence
•Physical verification of compliance via interviews and fact-based observations to confirm quality system requirements
•Evaluation of current special controls or validated processes; knowledgeable in various processes such as sterilization, clean-rooms, or software systems

Emergo Group also provides on-site ISO 13485 auditor training in order for clients to effectively audit their own quality systems. Our training is classroom-based and teaches your employees how to become ISO 13485 internal auditors to ensure proper functioning of your QMS. Key topics of the training include why ISO audits are required, planning an internal audit, as well as conduct and performance issues related to ISO 13485 internal audits.

CE Certification – CE Mark Certification for Medical DevicesSee all regulatory consulting services and medical device registration services.

In order to commercialize medical and in vitro diagnostic devices in the European Union, manufacturers must obtain CE Marking certification and affix the CE marking as part of their device registration efforts.

CE Marking certification verifies to EU regulators that your device meets all requirements of the Medical Devices Directive (MDD), In Vitro Diagnostic Device Directive (IVDD) or Active Implantable Medical Device Directive (AIMD) as they apply to your product. You must obtain CE Marking certification prior to marketing, distribution and sale of your product in any EU member state.

You are solely responsible as the medical device manufacturer for maintaining compliance with EU directives and securing CE Marking certification for your product, regardless of whether you outsource any or all components of your manufacturing operation.

Qualifying for CE certification and marketing your medical device in the EU requires the following steps:

1.Prepare a CE Marking Technical File or a Design Dossier for a Class III device that includes data proving compliance with the MDD, IVDD or AIMD.
2.Obtain your CE Marking certificate from a Notified Body.
3.Select and appoint a European Authorized Representative to act on your behalf within the EU.
4.Register your medical device with the appropriate Competent Authority, if necessary.
Completion of these requirements allows you to claim CE Marking certification for your device.

Looks like to me SNDY just took care of #3 with todays news.
Emergo Group has a well-established presence in the EU, with offices in the UK, Germany, France and the Netherlands. We have assisted hundreds of medical device manufactures with their CE Marking certification efforts. Services we provide to help you obtain CE certification include product classification; technical file and design dossier preparation; ISO 13485 quality system implementation and auditing; and ISO 14971 risk assessment and management.

Why choose Emergo Group as your ISO 13485 consultant?

With over 20 local offices worldwide, Emergo Group has helped hundreds of medical device and IVD manufacturers implement quality systems that meet the ISO 13485 standard. Our team of experienced ISO 13485 consultants have implemented numerous quality management systems for companies manufacturing a wide range of medical devices.

Our system has been proven to work efficiently and we have been through the process with many medical device and IVD companies that we guarantee you will pass your first ISO certification audit if you follow our plan.

•We fully customize ISO 13485 quality systems for our clients.
•Our ISO 13485 consulting and project management teams will work closely with you to ensure that your quality system is implemented on time and on budget.
•On-site ISO 13485, CE Marking, and Canadian Medical Devices Regulations training for your key employees is included in the cost of an Emergo Group quality system.
•All of our projects are based on a fixed price.


CE Mark Consultants and CE Marking for Medical Devices

Before you can sell a medical device or IVD within Europe, you must obtain CE Marking certification and place a CE Mark (CE Marking) on your product. The CE Marking for medical devices is not a quality mark nor is it intended for consumers. It is a legally binding statement by the manufacturer that their product has met all of the requirements of the Medical Devices Directive (MDD 93/42/EEC), In Vitro Diagnostic Device Directive (IVDD 98/79/EC) or the Active Implantable Medical Device Directive (AIMDD 90/385/EEC), where applicable. If a Notified Body is required, the Notified Body's four-digit number would appear below the CE Marking symbol.

CE Marking Checklist:
The Medical Devices Directives state that companies must do the following before they can place the CE Marking on a medical device or IVD:

•Compile a medical device CE Marking Technical File (or Design Dossier for Class III) with evidence of compliance to the Medical Devices Directive (or the IVD/AIMD Directives).
•Receive a medical device CE Mark certificate from a Notified Body if Class I with Measuring or Sterile function, Class IIa, IIb, or III, or if Annex II, List A; Annex II, List B, or self-testing IVD.
•Appoint a European Authorized Representative if you have no physical location in Europe.
•Register medical devices with the EU Competent Authorities, where applicable.

Only after these CE Marking requirements are satisfied are you allowed to place the CE Marking on your medical device.

Our CE Marking Services:
Emergo Group has assisted hundreds of companies with medical device CE Marking. Our services include:

•CE Marking Technical File or Design Dossier compilation and review.
•Verification of Essential Requirements.
•Product classification and identification of applicable standards for medical devices.
•Implementation and maintenance of ISO 13485 quality systems.
•Product labeling and packaging review.
•Risk assessment and management (ISO 14971).
•Development of Vigilance and Post Market Surveillance including Vigilance Standard Operating Procedures and Processes.
•Authorized Representative for Europe.
Our quality management systems can meet European CE Marking & other international requirements
Emergo Group can develop a compliant quality management system by applying ISO 13485:2012 to ensure you meet the quality system requirements for Europe. Each system is customized for the manufacturer and can not only ensure compliance to the European Directives for Medical Devices (CE Marking), but also to the Canadian Medical Devices Regulations, United States FDA QSR, Australian TGA requirements, and Japanese Pharmaceutical Affairs Law.

This place is like a Wal-Mart for your one stop shop for all your shopping needs.
Medical Device Logistics ConsultingEmergo Group can assist you with determining the best solutions for shipping your products. When exporting products many medical device companies start by shipping orders direct to distributors or customers. However, as the frequency of orders and order volumes increase it may become lucrative to consolidate orders in bulk shipments or to establish a suitable warehousing arrangement.

Warehousing & Transportation
In situations where companies are shipping direct to multiple distributors or customers, consolidation of these shipments may result in significantly lower shipping costs. And instead of requiring each distributor to keep a minimum inventory level, you as the supplier can decide to keep products warehoused in a centralized location to reduce total inventory levels in the supply chain while maintaining the option to ship next day to the distributors and customers. Results are cost savings in the supply chain, higher service levels to distributors and customers, and increased market share.

When importing products into Europe and warehousing these products in a centralized location, customs duties and value added tax (VAT) apply.

Customs Duties and Value Added Tax (VAT)
Postponement of customs duties can be arranged by warehousing your products in a customs bonded warehouse for an unlimited period of time. During this period no customs duties are due. Customs duties at import need to be paid when the goods are actually imported into the free circulation of the European Union.

Value Added Tax (VAT) is due upon import of products into the European Union and varies per EU country from 15-25%. This is a supply chain tax, and is refundable to businesses, usually by submitting a quarterly VAT return.

Finding and selecting warehousing & transportation partners
When looking for a third party logistics provider for your European warehousing and transportation needs, we can assist you with the following:

Step 1: Determine your medical device logistics needs
Depending on if you are starting up or optimizing your logistics operation(s), your needs can range from a distribution location to warehouse, pick, and ship your products to a full service value-added logistics facility where products can be assembled or customized to the specific needs of your customer base. The choice is yours! It is also possible to select a logistics provider as your fiscal representative.

Step 2: Identify potential EU logistics providers
Through our extensive logistics experience and existing network we are very familiar with the capabilities of logistics service providers specialized in medical devices. Based on your logistics needs we can identify the logistics providers that best fit your needs.

Step 3: Meet with potential logistics partners
Seeing is believing! We can set up on-site meetings for you with logistics providers that fit your needs and if required accompany you on these visits.

Well we don't know what it cost to hire Emergo Group, but I can say this, job well done SNDY for hiring such a great company to take this stock to the next level. If you had to sell some shares to make this happen, you spent our money well. I for one never questioned what was happening behind the doors at SNDY. I guess you can say the quite period is now over. I have said for the past 4 months when they have something of importance to tell us they will. I want to thank all the longs that has believed in SNDY over the past year and contributed to this board. I guess all those people spending 1.6 million dollars in SNDY preferred shares believed in them as well. We all know they was betting on the future of this company as well.

Take care my friends,
Mike
--------------------------------------------------------------------------------





Quote:
--------------------------------------------------------------------------------
ajsollii
Post # of 60019
When acquired, their shares would be absorbed and converted to the parent/new company's shares. No need to RS. The reason they gave was to make the company attractive to merger/acquisition. CE will do that nicely...as it did with the 95% of companies who exited via merger or acquisition after obtaining both CE and FDA approval. We know what's really going on. This is going to be a fun ride. $1? No. Not in the short term. But .25 isn't outside the realm of the possible. IMO...
--------------------------------------------------------------------------------




Quote:
--------------------------------------------------------------------------------
Looks like we have been warned over and over and over again that this stock will never go up because of all the diluted shares. Well according to the charts, if we compare price movement and volume the dilution is not hindering the stock price to run.
Lets go to bigcharts and see the facts for ourselves.

bigcharts.marketwatch.com/interchart/interchart.asp?symb=SNDY&insttype=Stock&time=20&freq=3

Once you open the link go to the left box click timeframe, then click chart range, then click 2 years.

Now lets look at volume and price movement. That is the telling story with the tradeable float. Slide your cursor on the bottom part of the chart and you will see for yourself the volume/date and price.
Date.............Price....Volume
Jan 27,2012 .0008 92,780,424
Feb 3, 2012 .001 138,243,856
Feb 10,2012 .003 148,966,600
Feb 17,212 .008 676,904,500
Total Volume 1,056,895,380 That is over 1 billion shares
traded in 3 weeks.
Float at this time was only 379,000,000

Date.............Price....Volume
March 9, 2012 .004 85,953,790
March 16,2012 .007 146,009,456
March 23,2012 .017 335,275,736
March 30,2012 .018 287,097,184
Total Volume 854,336,166 Over 3/4 million shares traded in
3 weeks and a 350% increase in price. Also remember we had big news that came out on March 23 that drove the price.
Float at this time was only 379,000,000.

Date...........Price....Volume
Feb 1,2013 .004 42,879,750
Feb 8,2013 .004 119,606,072
Feb 15,2013.006 103,673,360
Feb 22,2013.008 92,857,000
Total Volume 359,016,182, thats 58% less volume then the run we had from March 9th thru March 30th. Price increase of 100%.
Float at this time was 640,000,000.
A 41% increase in shares from the March 2012 run and yet the price moved just as easily.

Even the run up the July 18 went from .002 to .0038 on only 105,000,000 shares that day. Up over 80% and with a float of over 850,000,000 shares!!

These are FACTS that can't be dispelled no matter what anyone says. Yes the FACTS are they increased the O/S by 261 million shares during that time. But the FACTS also tells us those shares are not in the open market,(meaning when SNDY is selling these shares someone is buying them instead of them being just dumped into the open float of tradeable shares). If the float was that much bigger it would of taken at LEAST TWICE AS MUCH VOLUME TO MOVE THE STOCK PRICE UP ON THE RUN BACK IN FEBRUARY 2013.

I would agree with what many are saying about them diluting shares if they were being added to the tradeable float. The stock price would be very very hard to move up when you have a much larger float. But the FACTS shown in this chart with the price to volume ratio just do not support that the dilution will kill any run up in price. Sorry but it is simply the facts.

Yes SNDY has been selling shares but a lot of people on this board are buying. And this chart tells us that someone is buying them instad of them being dumped in the open market. Booper, Muff1, Blueski, Mgergo, Pennylanepam, Vert, Elcappy1, Frazier, Ichase01 and many others including myself have been buying millions of shares since February 2012. And the chart says exactly that.

Take care my friends,
Mike
--------------------------------------------------------------------------------




Quote:
--------------------------------------------------------------------------------
We are starting to see why big money...

has been investing in SNDY. The payoff is going to come when they get the CE mark approval. I have been adding every week for that past 3 months. My share totals no longer matters nor do the group of guys that are in this with me. I know what I own and have waited patiently for the payoff to come with a merger or partner/buyout with another medical company.

There is a reason these smart investors/venture capitalist are spending BIG money buying SNDY preferred shares. Remember this, investors that buy preferred shares are buying into the future of the company. They know what is coming and are taking a stake in the company. How much money are we talking about? Well here is the break down.

I have put together a list of the shares and the amount of money SNDY received by going thru their financial since 2nd Q 2011.

In the 2nd Q 2011 SNDY sold 4,000 preferred B stock options for $40,000 in cash. Bottom of Pg.19 of 4Q 2011 report.

In the 4th Q 2011 SNDY owed a contractor $400,000. This contractor took $400,000 worth of preferred B stock options and then gave SNDY $55,000 in cash for the purchase of additional shares. Pg.20 of 4Q 2011 report.

In the 1st Q 2012 a consultant received 26,000 shares of preferred B stock options for payment due of $260,000. Also they sold 10,900 share of preferred B stock options for $109,000 in cash. The entire board of SNDY also gave up their 150,000,000 shares of common stock to take preferred B stock options as well. Pg.15 of 1Q 2012 report.

In the 2nd Q 2012 the company sold 38,580 shares of preferred B stock options for 395,800 in cash. Also an officer and director took 27,015 shares of preferred B stock options for the conversion of $111,240 owed to him. Pg.15 of 2q 2012 report.

In the 3rd Q 2012 the company sold 26,150 shares of preferred B stock options for $261,500 in cash.Also the president recieved 450,000 shares of preferred B stock options for $450,000 owed to him for the signing of an employee contract and personal guarantees to the company. Pg.15 of 3q 2012 report.

There is obviously some major players with really deep pockets that have heavily invested into the future of SNDY. In cash advances to company alone they have received $861,300. Over 3/4 million dollars. Not to mention the contractors, consultants, and one officer receiving shares for money owed, in the amount of $771,240. Actually more cash money went into SNDY then people taking stock options as payments. That should say a lot. So we see that $1,632,540 in cash and stock option payments have been invested into the future of SNDY in a very short time. There is no one that is going to invest this kind of money into SNDY without knowing the payoff will be rewarding.

The thesis has been out for a few years and was one of the reasons while doing my DD that led me to buy so many shares of SNDY. One of the things that caught my attention a year ago in the thesis was at the end of page 52 and the first part of page 53. Here they are talking about venture capital investors buying preferred stock. And that is exactly what I saw with all the money going into SNDY with these investors buying preferred stock options. Also take a look at the last 2 paragraphs on page 83 and the first part of page 84. That is what SNDY did over the past 14 months, got cash flow positive and and reduced almost all debt.

I've been saying this company is in a quiet period and when it is time to release news they will. I'm glad they are not throwing out fluff PR's. It is giving me plenty of time to continue to buy more shares. I will stick by what I have said for the past 15 months. My money is invested into the future of SNDY and I believe my pay off will be well rewarding.

Take care my friends,
Mike

THIS SHOULD CLEAR ANY DOUBTS ABOUT A R/S...

If we want to use the history of SNDY past R/S, then you have to use all the history of SNDY past R/S. ALL THEIR PAST R/S DID EFFECT the preferred B shares. So if we are judging SNDY on their past actions, then we have to do so for the future as well.

Beside let’s cut to the real facts of a R/S. Even if they did a R/S say of 1 for 5000 do you realize how much smaller the float would be. This stock is so thin now can you imagine how thin it would be with a 1 for 5000 R/S. So with a float now of 660 million that would drop the float to 132,000 shares. Heck my entire group owns more then that.

So let’s do some math:
I've got 60,000,000 shares X .0078 = $468,000
After a 1 for 5,000 R/S I would then have 12,000 shares X $39.00 = $468,000. So I still have the same exact amount of money.

Now we would have a stock price at $39.00 with a float of only 132,000, and say at the same time they announce a partnership/merger along with news of them receiving the CE mark. Remember they have to have a European partner to obtain the CE mark. If you think the trading is tight not just imagine with the float dropping from 660 million, down to only 132,000 shares in the float. Talk about fuel for the fire. Also by having such a high share price of $39.00 it would remove the volatility even if they don't get the CE mark. I as an investor would welcome it. But I don't see it happening.

NOW THE REAL REASON WHY A R/S WANT HAPPEN.
If they do a 1 for 5000 R/S without effecting the preferred B shares like some keep saying. Then our COMMON SHARES at a R/S price of $39.00 would be worth more than the insiders preferred B stock options who only got $4.11 per share for their preferred B stock options when they gave up their 150 million common shares Feb 2012. The $4.11 per share figure was in the financial report.

So who in their right mind believes the insiders would actually allow our common shares to be worth more than their preferred B stock option share? FOLKS THAT IS NOT GOING TO HAPPEN!! I DON'T CARE HOW HARD ANYONE TRIES TO SPIN IT. SO IF THAT IS NOT GOING TO HAPPEN, THEN YOU HAVE TO BELIEVE A R/S IS NOT GOING TO HAPPEN. JUST SAYIN'

Take care my friends,
Mike

"Even though the auditors who are completing the CE Certification process have a 100% success record in attaining the CE Mark for clients, potential business partners may still want to wait until the Certification is successfully completed before they partner or merge with SNDY. However, if a potential partner is just as interested in bolstering up U.S. sales while waiting for European and Canadian sales to kick in, it could happen sooner."



--------------------------------------------------------------------------------





Quote:
--------------------------------------------------------------------------------
A/S 851M shares with just about 100M before being maxed. Highly unlikely the company increases A/S before a major milestone (CE Mark).

SNDY Current MC $1.702M. Obviously way undervalued even with the current S/S. SNDY BV $2.15M

I didn't particular like 190M new shares to hit the market (it reduces expected ROI) but it was as transparent as it comes. It hasn't been hard (at all) to track where the dilution is coming from, Preferred shares (that have been issued to Boost) are being converted to common shares. It's funny how nobody is talking about how all these shares have been absorbed at or above the 52 week low ahead of the CE Mark. $0.002 continues to be strong support.

The company has been able to continue carrying very little debt (Current Liabilities ~$173K). Solos has been able to keep its balance sheet very healthy despite how long the ISO process has taken. Costs associated with the CE Mark are finished, the company has the opportunity to reach quarterly profitability by increasing revenue a few hundred K.

Also important

Authorized Preferred Shares: 20M shares with only 650K outstanding.

No reason to authorize so many Preferred Shares if you don't expect to use them to generate capital.

A/S will likely increase at some point but the question is by how much. The CE Mark is a huge deal for a small medical device company looking to form a partnership or exit via M&A. CE Mark combined with international distribution would lead to a significantly higher PPS.

GLTA

mgrego


----

"With this complete service package, TUV SUD can assist medical companies in accessing markets nationally, in Europe, and globally."

The company that SOLOS has contracted with to enable them to attain the CE Certification has a 100% success record at accomplishing the CE Certification for companies it has worked with. The CE Mark is pretty much a given, but the street won't believe it until it is official. In the meantime, the most important event we are waiting for is the business partnerships the President of SOLOS alluded to in his letter to shareholders.
---

I don't recall "all" the longs here, or any for that matter, saying that SNDY is trading "great" now. However IMO it is best for the long term, to get all the peeps out of the stock that wanted to be overnight millionaires and replace them with actual INVESTORS in the company, not short term TRADERS or flippers of the stock. Being a shareholder of the company is not the same as being an investor in the company. Too many insecure faux long shareholders had their finger constantly hovering over the sell button, flinching and agonizing with daily ups and downs, instead of holding on to their stock and waiting for the positive, successful SNDY business story that has been gradually emerging and continues to unfold.
-

Penny stocks can eventually uplist to bigger boards like NASDAQ and AMEX. It takes time and patience. It does not happen overnight as the process from moving from the Pink Sheets, to the OTCBB and then to the AMEX or NASDAQ usually takes at least a couple of years. Over the last 15 years, I have owned penny stocks that eventually moved up and went from trading at .04 on the OTCBB, to trading at $4.00 on the AMEX . Unfortunately, I sold all but one of them while they were still pennies! They don't always make it once they move up to the NASDAQ or AMEX either. Nothing is easy .
---

The company is debt free and profitable. There is no more reason to dilute. They had to increase the A/S regardless, because the O/S had reached 495 mil, which left only 5 mil left in the A/S. That is a dangerous position for a company to be in. Anyone who thinks it would be better if the company did not raise the A/S, and sat with 495 out of 500 mil in the A/S are mistaken. Now the company has shares available for merger/acquisition/partnership. If they had not increased the A/S, they would be not be in a position to enter into those partnerships. They also had to protect themselves as they would have been vulnerable to hostile takeover from another company or person buying up a majority of shares.
--

Listen Jack, if you "know" so much about what a company automatically does after they increase the A/S, then you were foolish not to sell when the O/S reached 495 million out of 500 mil. Everyone had plenty of time to do so before the A/S increase. Once the O/S maxes out like that, a company would be negligent NOT to increase the A/S to protect itself and its shareholders. If you didn't know that, which is something that is basic knowledge when trading pinkies, then you certainly don't "know" what the company plans on doing next.

---

Few events strike as much fear in the hearts of start-up investors as dilution. Many go through great lengths to include anti-dilution clauses that protect the specific percent share of a company that they signed up for. If they buy or earn 10% of a company then they want to keep 10% of the company, often with little thought to the underlying value of the company. Dilution, however, isn’t necessarily a bad thing. In fact, dilution can be a great sign that your company is growing and doing the right things.
Dilution is a natural adjustment in ownership that occurs when the company distributes more shares to those who deserve it. So, if I own 50 out of 100 shares I own 50% of the company. If it’s a start-up company my 50% is probably worth nothing. However, if the company sells half the company for $1,000,000 and issues another 100 shares my ownership dilutes to 25% instead of 50%. However, the underlying value of my ownership went from being worthless to being worth $250,000. In this case, dilution is a good thing. I never would have built value in the company unless I was willing to be diluted.
Our fear of dilution will often have a negative impact on our ability to succeed. It will prevent us from bringing on valuable partners or employees that might deserve equity in our company. Our inability to realize that a small percent of something is infinitely better than a large percent of nothing holds us back.
The reason people fear dilution is because we don’t want to be taken advantage of by other participants in the company. If I invest in a company and receive 10% of 100 shares (10 shares) what’s to prevent the owners from simply granting more shares to themselves and diluting my shares with no gain in value? In this case other people will benefit at my expense. However, the reverse is also true. If the company has to issue me more stock whenever they issue stock to someone else I am essentially getting more stock for doing nothing. So, I am benefiting at the expense of others. Both scenarios are problematic. However, most of us would rather have the problem of getting more than we deserve.
In an ideal world every participant in the company would get exactly what they deserve—no more and no less. If we are all getting exactly what we deserve then there is no reason to worry about dilution. You can always rest assured that no matter what your share, it is always fair relative to others. The only way to achieve this, however, is through the use of a dynamic equity split program. Dynamic splits are not widely used today because they are not widely understood. Most companies use a fixed or static-split which is very difficult to keep fair. We try to compensate by using vesting programs, options programs and numerous protection clauses like anti-dilution. Equity negotiations are among the most painful and destructive events at a start-up. They pit people against each other who should be working together. It’s every man for himself.
However, in a dynamic equity model everyone is guaranteed to get what they deserve. In a dynamic model a relative value is put on the various contributions people make to the start-up. Contributions can include time, money, ideas, relationships, equipment, faculties and other necessities that help a business grow. You calculate ownership by dividing what you contributed by the total of all the contributions made by everyone on the team. Therefore, your percent ownership is always exactly what you should have. Dynamic models change during the early days of a start-up so dilution is a natural part of the process.
Dilution, under the right circumstances, is a positive sign that everyone in a start-up company is being treated fairly by everyone else. Under the wrong circumstances dilution is a sign of greed, mistrust and ego.







SNDY PR’s 2008 - 2013
06/06/2008 SNDY Completes Stock Split and Changes Symbol to SNDY
10/02/2008 SNDY and Its Products Appear in Worldwide Global Endoscopic Systems Market Report
10/08/2008 SNDY Posts First Six Months Financials of 2008 on Pinksheets.com
10/14/2008 SNDY in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
10/20/2008 SNDY Reports an 18% Increase in Sales during 3rd Quarter of 2008
10/23/2008 SNDY Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical C
10/30/2008 SNDY Mammo View(TM) System Now Used in Women's Hospital of Baton Rouge, LA
11/06/2008 SNDY Receives Purchase Order from Connecticut Hospital
11/14/2008 SNDY Mammo View(TM) System Introduced in Puerto Rico to Promote Breast Health
11/20/2008 SNDY Receives Purchase Order from Clarian Health Partners for Mammo View(TM) System
12/10/2008 SNDY Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year
01/06/2009 SNDY Receives Purchase Order from Cleveland Clinic
02/11/2009 SNDY Posts First Nine Months Financials for 2008 on Pinksheets.com
02/19/2009 SNDY MammoView(TM) Featured in December Issue of Surgical Products Magazine
02/24/2009 SNDY Breast Endoscopy System Featured in January Issue of Outpatient Surgery Magazine
02/26/2009 SNDY Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
03/03/2009 SNDY Successfully Completes FDA Inspection
03/20/2009 SNDY Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies
03/24/2009 SNDY Receives Purchase Order from Leading San Diego Healthcare Provider
04/02/2009 SNDY Develops Specialized Endocoupler for the MammoView(TM)
09/10/2009 SNDY Receives Purchase Order from One of the Major Healthcare Systems in Missouri
09/17/2009 SNDY Receives Purchase Order from the National Cancer Institute
09/21/2009 SNDY MammoView(TM) Product Line Receives New Purchase Orders Primarily from Prestigious Teaching Hospitals
09/23/2009 SNDY Receives Purchase Order from a University Teaching Hospital in Arkansas
09/29/2009 SNDY Receives Purchase Orders from Leading New York City Healthcare Center
10/06/2009 Small Company Offering and Sale of Securities Without Registration (D)
10/07/2009 SNDY MammoView(TM) Product Line to be demonstrated at the 95th Annual American College of Surgeons Clinical C
10/14/2009 SNDY FDA Approved MammoView(TM) Product Line to Obtain CE Mark
10/16/2009 SNDY Receives Multiple Purchase Orders for its MammoView(TM) Product Line
10/23/2009 SNDY Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for it
10/27/2009 SNDY Receives Purchase Orders from BJC HealthCare for its MammoView(TM) Product Line
10/29/2009 SNDY Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Pro
11/03/2009 SNDY Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
11/05/2009 SNDY Has Retained Services of Experienced Medical Marketing Firm for a 2010 Campaign
11/11/2009 SNDY Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
12/09/2009 SNDY Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
12/18/2009 SNDY Makes Significant Design Improvement to Its MammoView(TM) Ductoscope
12/23/2009 SNDY Outlines Marketing Strategy for 2010 Campaign
12/30/2009 SNDY Set to Increase Business through Sales and Product Development in 2010
01/15/2010 SNDY Breast Endoscopy System Featured in February Issue of General Surgery News
01/22/2010 SNDY Reports a 9% Increase in Sales for the 4th Quarter 2009 as Compared to 4th Quarter 2008
02/05/2010 SNDY Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
02/16/2010 SNDY Set To Develop New Polymer Dilator For MammoView(TM) System
03/18/2010 SNDY Granted U.S. Trademark for MammoView(R)
04/13/2010 SNDY Successfully Completes Phase One Requirements for ISO 13485 Quality Management System Initiative
04/16/2010 SNDY Posts Financial Results for Year Ending 2009
05/21/2010 Appoints Experienced CFO To Financial Leadership Amidst Growth
05/26/2010 SND Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
06/15/2010 Develops Relay Lense Adapter System For MammoView® Product Line
06/24/2010 Breast Endoscopy System Featured in July/August Issue of The Breast Journal
07/13/2010 SNDY Reports a 30% Increase in Sales for June 2010 as Compared to June 2009
08/26/2010 SNDY Reports Revenues for First Six Months of 2010
09/21/2010 SNDY to Hold Annual Shareholder Meeting September 28, 2010
09/30/2010 SNDY Announces Results of 2010 Annual Shareholder Meeting
10/27/2010 SNDY Revenue Grows 34.8% for Third Quarter 2010
11/19/2010 SNDY Announces Recapitalization Plan for 2011
01/06/2011 SNDY Trends toward Strong Continued Growth in 2011
01/27/2011 SNDY Reports $90,005 in Sales Revenue for Fourth Quarter 2010
02/10/2011 SNDY Reports $34,291 in Sales Revenue for January 2011
02/23/2011 SNDY To Introduce New Urology Instrument Line
03/24/2011 SNDY Strengthens Current Line of Laparoscopic Instruments
04/19/2011 SNDY Decreases Net Loss by Over $1 Million
06/14/2011 SNDY Receives Multiple Purchase Orders From Major Cancer Institutes and Research Centers
06/22/2011 Statement of Beneficial Ownership (SC 13D)
06/30/2011 SNDY Enters Multi-Billion Dollar Veterinary Market with Launch of Revamped Endoscopic Veterinary Product Line
06/23/2011 SNDY To Launch New Corporate Website
07/07/2011 Statement of Beneficial Ownership (SC 13D)
07/20/2011 SNDY MammoView® System Proves Crucial to Early Breast Cancer Detection
08/23/2011 SNDY to Reduce Debt by Over $620,000
09/15/2011 SNDY Reports 32% Increase in Breast Endoscopy Sales
09/23/2011 SNDY to Market its MammoView® Breast Endoscopy Components to US Hospitals
10/06/2011 SNDY to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US .
10/21/2011 SNDY Finishes the 3rd Quarter Strong
11/03/2011 SNDY Goes Google
11/17/2011 SNDY Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
11/22/2011 SNDY Finishes the 3rd Quarter With a Net Profit
12/22/2011 SNDY Reports Significant Sales From Its MammoView® Instrument Line
12/29/2011 SNDY is Primed for Growth in 2012
02/14/2012 SNDY Announces Retirement of 150 Million Common Shares
02/14/2012 Panache Beverages (WDKA) Presence Solid in the State of Florida
03/02/2012 SNDY Successfully Completes Level I FDA Inspection
03/16/2012 SNDY to Launch New SteriTAP™ Endoscopic Instrument Line
03/22/2012 SNDY and Opko Health Benefit From Booming Medical Equipment and Supplies Industry
03/30/2012 SNDY Reduces Net Loss by More Than $688,000
04/25/2012 SNDY Reduces Liabilities by More than $570,000
05/04/2012 SNDY to Finalize ISO 13485 Certification and CE Mark Initiative with Expert Resource for Endoscopic Instruments
04/30/2012 SNDY Sales Increase by 16% for First Quarter 2012
05/16/2012 SNDY Posts Net Profit for First Quarter 2012
05/23/2012 SNDY Releases ISO 13485 Certification and CE Mark Schedule With Work to Begin May 29
06/13/2012 SNDY Reduces Inventory Cost and Improves Gross Profit Margin for Second Quarter 2012
06/19/2012 SNDY to Expand Internationally its MammoView® Breast Endoscopy Product Line
07/13/2012 SNDY Begins Marketing the New SteriTAP(TM) Endoscopic Instrument Line
07/25/2012 SNDY Bariatric Instruments Are Now Available
08/16/2012 SNDY Posts Total Assets of $2,426,883 for Period Ended June 30, 2012
08/21/2012 SNDY Retains TUV SUD America to Complete ISO 13485 Certification and Audit
09/27/2012 SNDY Celebrates 25 Years of Quality Innovative HealthCare for the Multi-Billion Dollar Endoscopic Market
10/11/2012 SNDY Reports Significant Progress on ISO 13485 Certification and Audit
10/24/2012 SNDY Manufacturer to Conduct New Testing to Increase Sterilization Life for its MammoView® Breast Endoscopy
11/08/2012 SNDY Sales Increase by More than 35% for the Month of October
11/14/2012 Quarterly Report
11/15/2012 SNDY Reports Book Value of $2,393,522 for Period Ended September 30, 2012
12/14/2012 SNDY Sales Increases by More than 53% for the Month of November, 2012
12/14/2012 Attorney Letter with Respect to Current Information
12/14/2012 Quarterly Report
01/04/2013 SNDY Management Announces Goals for 2013
01/16/2013 SNDY Finishes 2012 Strong
01/24/2013 SNDY and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
03/04/2013 Officer/Director Disclosure

10:06 a.m. June 12, 2013
Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
1:01 p.m. July 18, 2013
Solos Endoscopy's MammoView(R) System Offers Women Early Breast Cancer Detection
9:06 a.m. Aug. 2, 2013
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe

****************************************************************

thats nice, did you know that SNDY will be ISO 13485 approved and CE Mark green light after friday? That makes SNDY a GLOBAL company. How many pinks are distributing products GLOBALLY?